Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Serum VEGF121 levels may predict anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody therapy efficacy in non-small-cell lung cancer. Higher serum VEGF121 levels correlated with shorter progression-free survival and lower objective response rates.
Area Of Science
- Oncology
- Immunotherapy
- Biomarker Discovery
Background
- Vascular endothelial growth factor (VEGF)-A influences the tumor microenvironment, impacting immunotherapy.
- VEGF-A isoforms (VEGF121, VEGF165) have differential effects on tumor growth.
- VEGF-A levels vary between serum and plasma, creating ambiguity in biomarker utility.
Purpose Of The Study
- To investigate the predictive value of serum and plasma VEGF-A levels (total and isoforms) for anti-PD-1/PD-L1 therapy efficacy.
- To determine if specific VEGF-A isoforms or measurements (serum vs. plasma) are superior predictors.
Main Methods
- Retrospective analysis of 86 non-small-cell lung cancer patients treated with anti-PD-1/PD-L1 monotherapy.
- Correlation of serum and plasma levels of total VEGF-A, VEGF121, and VEGF165 with progression-free survival (PFS) and objective response rate (ORR).
Main Results
- Higher serum total VEGF-A levels were associated with significantly shorter PFS.
- Plasma total VEGF-A levels did not stratify PFS.
- Elevated serum VEGF121 levels correlated with significantly shorter PFS and lower ORR.
- Multivariate analysis confirmed serum VEGF121 as a significant predictor of poorer outcomes.
Conclusions
- Serum VEGF121 levels show potential as a predictive biomarker for anti-PD-1/PD-L1 monotherapy efficacy in NSCLC.
- Serum measurement of VEGF121 may aid in patient selection for immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
